WorldMarketStudy: Market Research Reports

Wednesday, July 21, 2010

New Report Is Clean Coal a Reality: Green Edging through Carbon Capture and Storage added by WorldMarketStudy

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Content

WorldMarketStudy announces it Will Carry GlobalData’s Is Clean Coal a Reality: Green Edging through Carbon Capture and Storage June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/is-clean-coal-reality-green-edging-through-carbon-capture-storage-384.html

In response to the growing concern about climate change and rising greenhouse gas (GHG) emissions, considerable investment is going into looking for ways of continuing to burn coal, while reducing the atmospheric emissions of carbon and other pollutants. New clean coal technologies such as Carbon Capture and Storage (CCS) are expected to help contain the emissions, facilitating the use of coal in an environmentally satisfactory and economically viable manner as interim solutions to climate change.

While the available potential for CCS in the power industry is high, the adoption of CCS is plagued by various concerns surrounding the technology. Nevertheless, the future for CCS in utilities looks promising. Although end-user concerns regarding the Emission Trading System (ETS) and high costs are expected to hamper the commercial adoption of CCS in the near future, advanced research programs to develop new materials and the reformed ETS are going to address these issues. In addition, several collaborations and partnerships between governments, the power sector and research bodies have been actively pursuing innovative technological developments in carbon capture. The increasing success stories of smooth CCS integration and functioning are likely to reduce technological bottlenecks and raise the level of adoption.

Scope

Recent developments in the global carbon capture and storage market
Technological roadmap for carbon capture and storage technologies
Factors inhibiting the adoption of carbon capture and storage
Government support and incentives highlighted as the key driver to increase adoption of carbon capture and storage
Regional analysis of carbon capture and storage adoption
Strategies to spur development of carbon capture and storage technology

Reasons to buy

Identify key growth and investment opportunities in the global carbon capture and storage market
Position yourself to gain the maximum advantage of the industry’s growth potential by developing strategies
Facilitate decision-making based on upcoming global market developments in the carbon capture and storage market

1 Table of Contents
1.1 List of Figures

2 Summary

3 Green Edging through Carbon Capture and Storage
3.1 CCS – A “Clean Technology”: The Debate Rages On
3.2 Fiscal Support to Industries must for Development of CCS Technologies
3.3 Reduced Capital Cost to Spur Technology Adoption
3.4 Commercial Usage of CCS still a Distant Dream
3.5 Developmental Risks and Lack of Commercial Maturity plays Spoilsport
3.6 CCS in the European Union – A Cinderella Story
3.7 Lack of Long Term Policies in NA and China – Two of the Worlds Largest Carbon Emitters Discourage Investment
3.8 Horizontal and Vertical Integration Required to Create Synergies

4 Appendix
4.1 Methodology
4.2 Contact Us
4.3 Disclaimer

1.1 List of Figures
Figure 1: Clean Coal Technologies Development Roadmap, 2009 – 2025
Figure 2: Technology Roadmap for Carbon Capture and Storage , 2008 – 2030
Figure 3: GlobalData Methodology

View All Energy Market Reports http://www.worldmarketstudy.com/Energy-&-power-market-research-211.html

About WorldMarketStudy
In these days of cut-throat market competition, sole reliance on instincts is a dangerous proposition for any business person. Successful business can only be built on the solid background of well-researched information and knowledge based decisions.

And to aid these vital decisions, we at WorldMarketStudy offer you a one point solution for all your market research requirements. We have compiled a huge and constantly updated repository of more than 200,000 market search reports collected from over 650 research reports publishers. Browse all reports at http://www.worldmarketstudy.com/

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/

New Report Periodontal Disease – Drug Pipeline Analysis and Market Forecasts to 2016 added by WorldMarketStudy

WorldMarketStudy announces it Will Carry GlobalData’s Periodontal Disease – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/periodontal-disease-drug-pipeline-analysis-market-forecasts-2016-706.html

GlobalData, the industry analysis specialist’s new report, “Periodontal disease – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global periodontal disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global periodontal disease sector.

The global periodontal disease market was valued at $1,248m in 2009 and is characterized by efficacious dental procedures such as scaling, root planing and surgery. The periodontal therapeutics market comprises Local Applied Antibodies (LAAs) and systemic applied antibodies. The influx of new drugs and the increase in the uptake of LAAs will the drive the market in the forecast period. The various phases of the developmental pipeline contain 19 molecules. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The combinations of the tetracylines are expected to improve the efficacy of the treatment. However, the drug is similar in nature to doxycyclines. The entry of cost effective drugs in the forecast period is expected to aid the market growth.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

Annualized global periodontal disease market revenues data from 2001 to 2009, forecast for seven years to 2016.
Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France, and Japan.
Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include tetracycline antibiotics, osteoblast stimulators and anti-inflammatories, H+/K+ ATPase inhibitors; cell wall synthesis inhibitors.
Analysis of the current and future market competition in the global periodontal disease market. The key market players covered are Kaken Pharmaceutical, Fibrocell Science, Inc., and Combinatorx, Inc.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future periodontal disease market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global periodontal disease market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global periodontal disease market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global periodontal disease market landscape? – Identify, understand and capitalize

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Global Periodontal Disease: Market Characterization
2.1 Overview
2.1.1 Treatment Options
2.2 Periodontal Disease Market Size
2.3 Periodontal Disease Market Forecast and CAGR
2.4 Drivers and Barriers for the Periodontal Disease Market
2.4.1 Drivers for the Periodontal Disease Market
2.4.2 Barriers for the Periodontal Disease Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 Global Periodontal Disease Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Periodontal Disease Market
3.3.1 Periostat (Doxycycline Hyclate)
3.3.2 Arestin (minocycline hydrochloride microspheres)
3.3.3 Periochip (chlorhexidine gluconate)
3.3.4 Atridox (doxycycline hyclate 10%)
3.4 Key Takeaway

4 Global Periodontal Disease Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.3 Periodontal Disease Market – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Minocycline HCl
4.4.2 Trafermin (bFGF: Basic fibroblast growth factor)
4.5 Periodontal Disease Market – Clinical Pipeline by Mechanism of Action
4.5.1 Periodontal Disease – Phase III Clinical Pipeline
4.5.2 Periodontal Disease – Phase II Clinical Pipeline
4.5.3 Periodontal Disease – Phase I Clinical Pipeline
4.5.4 Periodontal Disease- Preclinical Pipeline
4.6 Key Takeaway

5 Global Periodontal Disease Market: Implications for Future Market Competition

6 Global Periodontal Disease Syndrome Market: Future Players
6.1 Introduction
6.2 Fibrocell Sciences, Inc
6.2.1 Company Overview
6.2.2 Business description
6.3 Orapharma
6.3.1 Company Overview
6.3.2 Business Description
6.4 Tolmar Inc
6.4.1 Company Overview
6.4.2 Business Description
6.5 Kaken Pharmaceutical
6.5.1 Overview
6.5.2 Business Description
6.6 Eli Lilly & Company
6.6.1 Company Overview
6.6.2 Business Description

7 Periodontal disease Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panels
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 List of Tables
Table 1: Various Types of Medications Employed in Treating the Periodontal Disease 6
Table 2: Periodontal Disease, Global, Historical Revenue ($m), 2001-2009 7
Table 3: Periodontal Disease, Global, Forecasted Reveune ($m), 2009-2016 8
Table 4: Major Marketed Products Comparison in Periodontal Disease Market, 2010 16
Table 5: Periodontal Disease – Most Promising Drugs Under Clinical Development, 2010 20
Table 6: Periodontal Disease – Phase III Clinical Pipeline, 2010 22
Table 7 Periodontal Disease- Phase II Clinical Pipeline, 2010 22
Table 8 Periodontal Disease – Phase I Clinical Pipeline, 2010 23
Table 9: Periodontal Disease – Preclinical Pipeline, 2010 23
Table 10: Fibrocell Sciences, Inc – Periodontal disease Pipeline Product Portfolio, 2010 26
Table 11: Genzyme Corporation – Periodontal Disease Pipeline Product Portfolio, 2010 26
Table 12: Tolmar, Inc – Periodontal Disease Pipeline Product Portfolio, 2010 27
Table 13: Kaken Pharmaceutical – Periodontal Pipeline Product Portfolio, 2010 28
Table 14: Eli Lilly – Periodontal Disease Pipeline Product Portfolio, 2010 29

1.2 List of Figures
Figure 1: Periodontal Disease, Global, Historical Revenue ($m), 2001-2009
Figure 2: Periodontal Disease, Global, Forecasted Revenue ($m), 2009-2016
Figure 3: Opportunity and Unmet Need in the Periodontal Disease Market, 2010
Figure 4: Strategic Competitor Assessment, 2010
Figure 5: Pipeline Products by Phase of Development, 2009
Figure 6: Technology Trends Analytics Frame Work, 2010
Figure 7: Technology Trends Analytics Frame Work – Description, 2010
Figure 8: Periodontal Disease Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 9: Periodontal Disease Market – Clinical Pipeline by Phase of Development, 2010
Figure 10: Implications for Future Market Competition in the Periodontal Disease Market, 2010
Figure 11: Periodontal Disease Market – Clinical Pipeline by Company, 2010
Figure 12: GlobalData Methodology, 2010
Figure 13: GlobalData Market Forecasting Model, 2010

View All Pharmaceuticals Market Reports http://www.worldmarketstudy.com/Pharmaceuticals-market-research-4.html

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/

New Report Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016 added by WorldMarketStudy

WorldMarketStudy announces it Will Carry GlobalData’s Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/hemophilia-drug-pipeline-analysis-market-forecasts-2016-500.html

GlobalData’s pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global hemophilia market was valued at $6.5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.

Scope

The scope of the report includes:

Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.
Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.
Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N.V., Novo Nordisk.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global haemophilia market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global haemophilia market landscape? – Identify, understand and capitalize

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Hemophilia Market: Market Characterization
2.1 Overview
2.2 Hemophilia Therapeutics Market Size
2.3 Hemophilia Therapeutics Market Forecast and CAGR
2.4 Drivers and Barriers for the Hemophilia Therapeutics Market
2.4.1 Drivers for the Hemophilia Therapeutics Market
2.4.2 Barriers for the Hemophilia Therapeutics Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 Hemophilia Therapeutics Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market
3.3.1 NovoSeven
3.3.2 Kogenate FS
3.3.3 Xyntha
3.3.4 Advate
3.4 Key Takeaway

4 Hemophilia Therapeutics Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Hemophilia Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Ataluren (PTC124)
4.4.2 NecLip-rFVIIa (LongSeven)
4.4.3 rFVIII (Recombinant factor VIIa (N8))
4.5 Hemophilia Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Hemophilia Therapeutics Pipeline – Pipeline by Clinical Phase of Development
4.6.1 Hemophilia Therapeutics – Phase III Clinical Pipeline
4.6.2 Hemophilia Therapeutics – Phase II Clinical Pipeline
4.6.3 Hemophilia Therapeutics – Phase I Clinical Pipeline
4.6.4 Hemophilia Therapeutics – Pre-clinical Pipeline
4.7 Key Takeaway

5 Hemophilia Therapeutics Market: Implications for Future Market Competition

6 Hemophilia Therapeutics Market: Future Players in the Hemophilia Therapeutics Market
6.1 Introduction
6.2 PTC Therapeutics
6.2.1 Overview
6.2.2 Hemophilia Portfolio
6.2.3 Hemophilia Pipeline Portfolio
6.2.4 Ataluren (PTC124)
6.3 Recoly N.V.
6.3.1 Overview
6.3.2 Hemophilia Portfolio
6.3.3 Hemophilia Pipeline Portfolio
6.3.4 NecLip-rFVIIa (LongSeven)
6.4 Novo Nordisk
6.4.1 Overview
6.4.2 Hemophilia Portfolio
6.4.3 Hemophilia Pipeline Portfolio
6.4.4 rFVIII (Recombinant factor VIIa (N8))

7 Hemophilia Therapeutics Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 List of Tables
Table 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009
Table 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016
Table 3: Major Marketed Products Comparison in the Hemophilia Therapeutics Market, 2010
Table 4: Hemophilia Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 5: Hemophilia Therapeutics – Phase III Clinical Pipeline, 2010
Table 6: Hemophilia Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: Hemophilia Therapeutics – Phase I Clinical Pipeline, 2010
Table 8: Hemophilia Therapeutics – Pre-Clinical Pipeline, 2010
Table 9: PTC Therapeutics, Inc. – Hemophilia Pipeline Products, 2010
Table 10: Recoly N.V. – Hemophilia Pipeline Products, 2010
Table 11: Novo Nordisk – Hemophilia Pipeline Products, 2010

1.2 List of Figures
Figure 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009
Figure 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016
Figure 3: Opportunity and Unmet Need in the Hemophilia Therapeutics Market, 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Hemophilia Therapeutics, 2010
Figure 5: Technology Trends Analytic Framework of the Hemophilia Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Hemophilia Therapeutics Pipeline – Description, 2010
Figure 7: Hemophilia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010
Figure 8: Hemophilia Therapeutics Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Hemophilia Therapeutics Market, 2010
Figure 10: Hemophilia Therapeutics Market – Clinical Pipeline by Company (No. of Molecules), 2010
Figure 11: GlobalData Methodology, 2010
Figure 12: GlobalData Market Forecasting Model, 2010

View All Pharmaceuticals Market Reports http://www.worldmarketstudy.com/Pharmaceuticals-market-research-4.html

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/

New Report Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016 added by WorldMarketStudy

WorldMarketStudy announces it Will Carry GlobalData’s Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/pneumonia-drug-pipeline-analysis-market-forecasts-2016-501.html

GlobalData’s pharmaceutical and healthcare report offering, “Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016”. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.

Scope

The scope of the report includes:

Annualized global pneumonia market revenues data from 2000 to 2009, forecast for seven years to 2016.
Key geographies covered in this report include the Unites States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action are cell wall synthesis inhibitors, protein synthesis inhibitors and topoisomerase II and topoisomerase IV inhibitors.
Analysis of the current and future market competition in the global pneumonia market. The key market players covered are AstraZeneca, Pfizer, Bayer, GSK and J&J Pharmaceuticals.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future pneumonia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global pneumonia market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pneumonia market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global pneumonia market landscape? – Identify, understand and capitalize

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Pnemonia Therapeutics Market: Market Characterization
2.1 Overview
2.2 Pneumonia Therapeutics Market Size
2.3 Pneumonia Therapeutics Market Forecast and CAGR
2.4 Drivers and Barriers for the Pneumonia Therapeutics Market
2.4.1 Drivers for the Pneumonia Therapeutics Market
2.4.2 Barriers for the Pneumonia Therapeutics Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 Pneumonia Therapeutics Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Portfolio for Major Marketed Products in the Pneumonia Therapeutics Market
3.3.1 Zyvox (linezolid)
3.3.2 Zosyn (piperacillin and tazobactam)
3.3.3 Levaquin (levofloxacin)
3.3.4 Avelox (moxifloxacin)
3.3.5 Omnicef (cefdinir)
3.3.6 Tygacil (tigecycline)
3.3.7 Doribax (doripenem)
3.4 Key Takeaway

4 Pneumonia Therapeutics Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytical Framework
4.3 Pneumonia Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profiles for Promising Drugs under Clinical Development
4.4.1 Ceftaroline
4.4.2 Ceftobiprole medocaril
4.4.3 Restanza (cethromycin)
4.4.4 Vibativ (telavancin)
4.5 Pneumonia Therapeutics Market – Pipeline Assessment by Mechanism of Action
4.6 Pneumonia Therapeutics Market – Pipeline Assessment by Phase of Clinical Development
4.6.1 Pneumonia Therapeutics – Phase III Clinical Pipeline
4.6.2 Pneumonia Therapeutics – Phase II Clinical Pipeline
4.6.3 Pneumonia Therapeutics – Phase I Clinical Pipeline
4.6.4 Pneumonia Therapeutics – Preclinical Pipeline
4.6.5 Pneumonia Therapeutics – Discovery Pipeline
4.7 Discontinued/Suspended Drugs for Pneumonia
4.8 Key Takeaway

5 Pneumonia Therapeutics Market: Implications for Future Market Competition

6 Pneumonia Therapeutics Market: Future Players in the Pneumonia Therapeutics Market
6.1 Forest Laboratories, Inc.
6.1.1 Company Overview
6.1.2 Ceftaroline
6.2 Basilea Pharmaceutica
6.2.1 Company Overview
6.2.2 Ceftobiprole medocaril
6.3 Advanced Life Sciences
6.3.1 Company Overview
6.3.2 Restanza (cethromycin)
6.4 Theravance, Inc.
6.4.1 Company Overview
6.4.2 Vibativ (telavancin)

7 Pneumonia Therapeutics Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.4 Coverage
7.5 Secondary Research
7.6 Primary Research
7.7 Models
7.8 Forecasts
7.9 Expert Panels
7.10 Sources
7.11 GlobalData Consulting
7.12 Contact Us
7.13 Disclaimer
1.1 List of Tables
Table 1: Empirical Antimicrobial Therapy for Pneumonia, 2010
Table 2: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009
Table 3: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 4: Cure Rates of Zyvox in Nosocomial Pneumonia, 2010
Table 5: Cure Rates of Zyvox in Community-Acquired Pneumonia due to MDRSP, 2010
Table 6: Pneumonia Therapeutics Market, Global, Most Promising Molecules under Clinical Development, May 2010
Table 7: Pneumonia Therapeutics Market, Global, Phase III Clinical Pipeline, 2010
Table 8: Pneumonia Therapeutics Market, Global, Phase II Clinical Pipeline, 2010
Table 9: Pneumonia Therapeutics Market, Global, Phase I Clinical Pipeline, 2010
Table 10: Pneumonia Therapeutics Market, Global, Preclinical Pipeline, 2010
Table 11: Pneumonia Therapeutics Market, Global, Discovery Pipeline, 2010
Table 12: Pneumonia Therapeutics Market, Global, List of Discontinued Drugs, 2010
1.2 List of Figures
Figure 1: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009
Figure 2: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Figure 3: Pneumonia Therapeutics Market, Global, Opportunity and Unmet Need, 2010
Figure 4: Pneumonia Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products, 2010
Figure 5: Pneumonia Therapeutics Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 6: Pneumonia Therapeutics Market, Global, Technology Trends Analytic Framework, Description—2010
Figure 7: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Pneumonia Therapeutics Market, Global, Clinical Pipeline, 2010
Figure 9: Pneumonia Therapeutics Market, Global, Implications for Future Market Competition, 2010
Figure 10: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Company, 2010
Figure 11: GlobalData Methodology, 2010

View All Pharmaceuticals Market Reports http://www.worldmarketstudy.com/Pharmaceuticals-market-research-4.html

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/

Tuesday, July 20, 2010

New Report Mergers & Acquisitions Deal Analysis – MEMC Electronic Materials To Acquire Solaicx added by WorldMarketStudy

WorldMarketStudy announces it Will Carry GlobalData’s Mergers & Acquisitions Deal Analysis – MEMC Electronic Materials To Acquire Solaicx June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/mergers-acquisitions-deal-analysis-memc-electronic-materials-acquire-solaicx-776.html

MEMC Electronic Materials, Inc. (MEMC), a manufacturer of wafers, has entered into a definitive agreement to acquire Solaicx, Inc. (Solaicx), a manufacturer of solar photovoltaic ingots and wafers. Under the terms of the agreement, MEMC will pay around $103.6 million to Solaicx. The execution of the deal will help MEMC in expanding its footprint in the industry by acquiring Solaicx’s customer base, proprietary process and equipment, and in improving the company’s bottom line.

Scope

The information related to the acquisition of Solaicx.
A brief on companies Solaicx Inc.and MEMC Electronic Materials, Inc.
Comparison of deals in the Solar PV Sector
The rationale behind acquisition by First Solar

Reasons to buy

The Deal Report attempts to focus on the reason behind the acquisition by MEMC Electronic Materials, Inc.It will allow the reader to:

Understand the reasons for the acquisition.
Analyze similar acquisition opportunities in the region and compare with the acquisition in the other regions.
Assists in understanding the solar market of US

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Summary

3 MEMC Electronic Materials To Acquire Solaicx
3.1 Deal Overview
3.2 Deal In Brief
3.3 Comparable Deals
3.4 About the Companies
3.5 Deal Rationale
3.6 Deal Analysis

4 Appendix
4.1 Methodology
4.2 Contact Us
4.3 Disclaimer

1.1 List of Tables
Table 1: Comparable Deals in the Solar PV Sector

1.2 List of Figures
Figure 1: MEMC and NASDAQ Movement, 20 May 2010 – 28 May 2010
Figure 2: GlobalData Methodology

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/

New Report Mergers & Acquisitions Deal Analysis – CNPC Acquires 35% Interest In Syria Shell Petroleum Development added by WorldMarketStudy

WorldMarketStudy announces it Will Carry GlobalData’s Mergers & Acquisitions Deal Analysis – CNPC Acquires 35% Interest In Syria Shell Petroleum Development June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/mergers-acquisitions-deal-analysis-cnpc-acquires-35percent-interest-syria-shell-petroleum-development-795.html

China National Petroleum Corporation (CNPC), an integrated energy company, acquired a 35% interest in Syria Shell Petroleum Development B.V. (SSPD), an oil exploration and production company, from Royal Dutch Shell plc (Shell).

The transaction will enable CNPC to further expand its presence in upstream business in Syria.

Scope

Rationale behind CNPC’s acquisition of an interest in Syria Shell Petroleum development (SSPD)
Strategic Benefits for SSPD to merge with CNPC
Geography covered – Syrian Arab Republic
Deal Financials and Valuations
Information on CNPC and Royal Dutch Shell

Reasons to buy

Develop a sound undestanding of the major M&A’s, Partnerships, Joint Ventures and Asset Transactions taking place in North American Oil & Gas industry
Identify the most lucrative segments to leverage on the growth oppurtunities available in the Syrian oil & gas market
Get a detailed analysis of a deal to enable you to take better decisions
Know about the major companies, which are adopting a divestment or acquisition strategy to enhance their business portfolios
Learn about the key fiancial advisors in a particular segment in the Oil & Gas Industry
Understand the various means of raising funds from the market

1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 GlobalData Deal Analysis
2.1 Summary
2.2 Deal Overview
3 CNPC Acquires 35% Interest In Syria Shell Petroleum Development
3.1 Deal Overview
3.2 Deal in Brief
3.3 CNPC Expands its Business Presence in Syria by Acquiring a Stake in SSPD
3.4 CNPC Plans to Consolidate its Position in the Upstream Sector through its Partnership with Shell
3.5 Shell’s Divestment of its Syrian Assets is a part of the Company’s Strategy to Sell its Non-Core Assets
3.6 Deal Financials and Valuations
3.6.1 Companies Involved
3.6.2 Deal Financials
3.6.3 Deal Rationale
3.6.4 Detailed Target Information
3.6.5 Production and Reserves Information
3.6.6 Detailed Acquirer Information
3.6.7 Detailed Vendor Information
4 Appendix
4.1 About Energy eTrack
4.2 Methodology
4.2.1 Coverage
4.2.2 Secondary Research
4.2.3 Primary Research
4.2.4 Expert Panel Validation
4.3 Contact Us
4.4 Disclaimer
1.1 List of Tables
Table 1: CNPC, Major Acquisition Details, 2005-10
Table 2: Shell, Major Divestment Details, 2008-10
Table 3: Key Companies Involved in the Deal
Table 4: Financials of the Deal, 2010
Table 5: Target Information
Table 6: Target’s Production and Reserves Information, 2010
Table 7: Acquirer Information
Table 8: Vendor Information
1.2 List of Figures
Figure 1: CNPC, Global Operations Map, 2010
Figure 2: GlobalData Methodology

Mergers & Acquisitions Deal Analysis – Petrobras To Acquire 50% Interest In Cascade Field From Devon Energy

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/

New Report Mergers & Acquisitions Deal Analysis – SandRidge Energy to Merge with Arena Resources added by WorldMarketStudy

WorldMarketStudy announces it Will Carry GlobalData’s Mergers & Acquisitions Deal Analysis – SandRidge Energy to Merge with Arena Resources June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/mergers-acquisitions-deal-analysis-sandridge-energy-merge-arena-resources-796.html

SandRidge Energy, Inc (SandRidge Energy) entered into a definitive merger agreement with Arena Resources, Inc (Arena Resources) in a stock and cash transaction. The transaction is valued at approximately $1.6 billion. Under the terms of agreement, Arena Resources’ shareholders will receive stock and cash consideration valued at $40 per share of Arena Resources common stock based on SandRidge Energy’s April 1, 2010 closing price. The offer price represents a 17% premium for Arena Resources shareholders. SandRidge Energy will issue 4.7771 shares of common stock and pay $2.50 in cash for each share of Arena Resources common stock, resulting in a combined enterprise value of approximately $6.2 billion.

Following the transaction, SandRidge Energy will be the surviving company, headquartered in Oklahoma City and its management team will continue in their current roles. The combined company will have more than 200,000 net acres in the Permian Basin and 5,700 identified locations to drill primarily in the shallow San Andres and the Clear Fork formations. SandRidge Energy also owns low risk natural gas properties in the Pinon Field, and significant exploration opportunities in the West Texas Overthrust.

Deutsche Bank Securities Inc. is serving as financial and Covington & Burling LLP is acing as legal advisor to SandRidge Energy where as Tudor, Pickering, Holt & Co. Securities, Inc. is acting as financial advisor and Johnson & Jones, P.C. is acting as legal advisor to Arena Resources with respect to the transaction. The transaction is expected to complete in June or July 2010

Scope

Rationale behind Sandridge Energy’s acquisition of Arena Resources in the US
Strategic Benefits for Arena Resources to merge with Sandridge Energy
Geography covered – US
Deal Financials and Valuations
Information on Sandridge Energy Inc. and Arena Resources Inc.

Reasons to buy

Develop a sound undestanding of the major M&A’s, Partnerships, Joint Ventures and Asset Transactions taking place in North American Oil & Gas industry
Identify the most lucrative segments to leverage on the growth oppurtunities available in the US oil & gas market
Get a detailed analysis of a deal to enable you to take better decisions
Know about the major companies, which are adopting a divestment or acquisition strategy to enhance their business portfolios
Learn about the key fiancial advisors in a particular segment in the Oil & Gas Industry
Understand the various means of raising funds from the market

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 GlobalData Deal Analysis
2.1 Summary
2.2 Deal Overview

3 SandRidge Energy to Merge with Arena Resources
3.1 Deal Overview
3.2 Deal In Brief
3.3 SandRidge Energy is Acquiring Arena Resources to Further Consolidate its Position in West Texas
3.4 SandRidge Energy is Acquiring Oil Assets to Develop a More Balanced Portfolio
3.5 Arena Resources’ Assets Overview
3.5.1 New Mexico
3.5.2 Texas
3.5.3 Oklahoma
3.5.4 Kansas
3.6 SandRidge Energy Has Acquired Arena Resources at a Premium as Compared to Other Recent Transactions
3.7 Deal Financials and Valuations:
3.7.1 Companies Involved
3.7.2 Deal Financials
3.7.3 Deal Rationale
3.7.4 Advisor Information
3.7.5 Detailed Target Information
3.7.6 Key Financials:
3.7.7 Share Price Information
3.7.8 Company Valuation Multiples
3.7.9 Detailed Target Information
3.7.10 Key Financials:
3.7.11 Share Price Information
3.7.12 Company Valuation Multiples
3.7.13 Production and Reserves Information
3.7.14 Transaction Implied Values
3.7.15 Commodity Prices Information

4 Appendix
4.1 About Energy eTrack
4.2 Methodology
4.2.1 Coverage
4.2.2 Secondary Research
4.2.3 Primary Research
4.2.4 Expert Panel Validation
4.3 Contact Us
4.4 Disclaimer

1.1 List of Tables
Table 1: SandRidge Energy, Performa Acquisition Details, 2010
Table 2: The US, E&P Assets, Transaction and Acquisition Details, January 2010 – April 2010
Table 3: Key Companies Involved in the Deal
Table 4: Financials of the Deal, 2010
Table 5: Advisor Information
Table 6: Target Information
Table 7: Arena’s Financial Information, 2010
Table 8: Arena’s Share Price Information, 2010
Table 9: Arena’s Valuation Multiples, 2010
Table 10: Target Information
Table 11: SandRidge Energy’s Financial Information, 2010
Table 12: SandRidge Energy’s Share Price Information, 2010
Table 13: SandRidge Energy’s Valuation Multiples, 2010
Table 14: Arena Resources’ Production and Reserves Information, 2010
Table 15: Transaction Implied Values, 2010
Table 16: Commodity Prices in $, Last Close, 2010

1.2 List of Figures
Figure 1: SandRidge Energy, Operations Map, 2010
Figure 2: SandRidge Energy, Post Acquisition, West Texas Assets Map, 2010
Figure 3: SandRidge Energy, Post Acquisition, Central Basin Platform Map, 2010
Figure 4: Arena Resources, Operations Map, 2010
Figure 5: GlobalData Methodology

Mergers & Acquisitions Deal Analysis – MarkWest Energy Sells Its 50% Interest in Stingray Pipeline

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/